Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INTERPRETE: a Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity

NCT06952101 is registered in ClinicalTrials.gov with Fondazione del Piemonte per l'Oncologia as lead sponsor.

NCT NCT06952101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06952101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INTERPRETE: a Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Phase
Not applicable
Overall status
Recruiting
Start date
April 30, 2024
Completion date
December 31, 2030
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non metastatic, rectal adenocarcinoma